Update on options for treatment of metastatic castration-resistant prostate cancer.

PubWeight™: 1.00‹?› | Rank: Top 15%

🔗 View Article (PMC 2895780)

Published in Onco Targets Ther on June 24, 2010


Prakash Vishnu1, Winston W Tan

Author Affiliations

1: Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL, USA.

Associated clinical trials:

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT00638690

Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM) | NCT00974311

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (READY) | NCT00744497

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC) | NCT00417079

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE) | NCT00519285

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy | NCT00134056

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00110214

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C) | NCT00617669

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy (SUN 1120) | NCT00676650

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1) | NCT00554229

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0) | NCT00626548

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer | NCT00255606

Articles citing this

Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47

CXCR4 expression in prostate cancer progenitor cells. PLoS One (2012) 1.25

Mouse models of prostate cancer. Prostate Cancer (2011) 1.04

Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol (2012) 0.94

The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res (2012) 0.88

Activation of Wnt/β-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia. Prostate (2014) 0.84

Complete regression of advanced prostate cancer for ten years: A case report and review of the literature. Oncol Lett (2013) 0.80

Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem (2015) 0.79

Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res (2016) 0.76

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer (2012) 0.76

NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis. PLoS One (2014) 0.75

Active Holistic Surveillance: The Nutritional Aspect of Delayed Intervention in Prostate Cancer. J Nutr Metab (2016) 0.75

Articles cited by this

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37

Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02

BCL-2 family: regulators of cell death. Annu Rev Immunol (1998) 6.41

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05

Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med (2004) 2.89

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther (2005) 2.70

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med (1995) 2.50

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer (1995) 2.10

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90

A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 1.77

Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res (2009) 1.72

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72

Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol (2002) 1.70

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol (2009) 1.67

Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res (2003) 1.55

Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52

SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res (2009) 1.47

Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol (2004) 1.43

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol (2005) 1.39

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem (2009) 1.36

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer (2007) 1.36

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology (2005) 1.34

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol (2005) 1.33

Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol (2009) 1.28

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 1.23

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.23

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol (2009) 1.19

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer (2003) 1.13

The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs (2004) 1.12

Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia (2001) 1.02

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol (2011) 1.00

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs (2005) 0.98

Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol (2008) 0.96

Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology (2007) 0.91

The role of stress proteins in prostate cancer. Curr Genomics (2007) 0.88

Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res (2006) 0.87

Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res (1994) 0.86

Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep (2005) 0.85

Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep (2003) 0.84

Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis (2004) 0.83

Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep (2006) 0.80

Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J (2003) 0.79

Articles by these authors

Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res (2013) 2.00

Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res (2006) 1.51

Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer (2008) 1.05

Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs (2005) 0.97

The role of mammography in male patients with breast symptoms. Mayo Clin Proc (2007) 0.93

Quality of life of men with biochemical recurrence of prostate cancer. J Psychosoc Oncol (2008) 0.91

Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther (2011) 0.90

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Breast Cancer (Auckl) (2011) 0.89

Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma. J Psychosoc Oncol (2011) 0.84

Sorafenib-induced pancreatitis. Mayo Clin Proc (2007) 0.81

Treatment of men with rising prostate-specific antigen levels following radical prostatectomy. Expert Rev Anticancer Ther (2011) 0.80

Cushing's syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med (2008) 0.80

Editorial comment. Urology (2010) 0.75

Re: Greil et al.: Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals (Urology 2009;73:631-634). Urology (2009) 0.75

Medical image. papules of unknown aetiology. Disseminated Curvularia. N Z Med J (2012) 0.75

The management of bone loss in patients with breast or prostate cancer. Support Cancer Ther (2004) 0.75

A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psychooncology (2010) 0.75